Slate runs a great piece today on why pharmaceutical companies fund bioethicists, and how this is part of “a larger strategy: buying off the entire apparatus of academic medicine.” It nicely summarizes the dangers that any scholar who seeks (or has no choice but to accept) engagement with the marketplace faces.

Not that I would know anything about such things. But if a PR agency wants to write an article for me, get in touch.

And I still wish the LA Times book review was available to non-subscribers. It doesn’t make any sense: the regular paper, which is going to attract about a zillion more readers, is free, but this tiny part of it that deals with cultural stuff is protected behind a subscriber firewall. Grrrrr.